Role of MHC class I pathways in Mycobacterium tuberculosis antigen presentation
- PMID: 37009503
- PMCID: PMC10050577
- DOI: 10.3389/fcimb.2023.1107884
Role of MHC class I pathways in Mycobacterium tuberculosis antigen presentation
Abstract
MHC class I antigen processing is an underappreciated area of nonviral host-pathogen interactions, bridging both immunology and cell biology, where the pathogen's natural life cycle involves little presence in the cytoplasm. The effective response to MHC-I foreign antigen presentation is not only cell death but also phenotypic changes in other cells and stimulation of the memory cells ready for the next antigen reoccurrence. This review looks at the MHC-I antigen processing pathway and potential alternative sources of the antigens, focusing on Mycobacterium tuberculosis (Mtb) as an intracellular pathogen that co-evolved with humans and developed an array of decoy strategies to survive in a hostile environment by manipulating host immunity to its own advantage. As that happens via the selective antigen presentation process, reinforcement of the effective antigen recognition on MHC-I molecules may stimulate subsets of effector cells that act earlier and more locally. Vaccines against tuberculosis (TB) could potentially eliminate this disease, yet their development has been slow, and success is limited in the context of this global disease's spread. This review's conclusions set out potential directions for MHC-I-focused approaches for the next generation of vaccines.
Keywords: MHC-I; Mycobacterium tuberculosis; antigen processing; cytotoxic T cells; host-pathogen interactions; vaccine.
Copyright © 2023 Witt.
Conflict of interest statement
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures

Similar articles
-
Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection.Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11786-91. doi: 10.1073/pnas.93.21.11786. Proc Natl Acad Sci U S A. 1996. PMID: 8876215 Free PMC article.
-
Harnessing donor unrestricted T-cells for new vaccines against tuberculosis.Vaccine. 2019 May 21;37(23):3022-3030. doi: 10.1016/j.vaccine.2019.04.050. Epub 2019 Apr 27. Vaccine. 2019. PMID: 31040086 Free PMC article. Review.
-
Mycobacterium tuberculosis PPE18 protein inhibits MHC class II antigen presentation and B cell response in mice.Eur J Immunol. 2021 Mar;51(3):603-619. doi: 10.1002/eji.201848071. Epub 2020 Dec 1. Eur J Immunol. 2021. PMID: 33084017
-
A lipidated bi-epitope vaccine comprising of MHC-I and MHC-II binder peptides elicits protective CD4 T cell and CD8 T cell immunity against Mycobacterium tuberculosis.J Transl Med. 2018 Oct 11;16(1):279. doi: 10.1186/s12967-018-1653-x. J Transl Med. 2018. PMID: 30305097 Free PMC article.
-
Host immune response to intracellular bacteria: A role for MHC-linked class-Ib antigen-presenting molecules.Proc Soc Exp Biol Med. 2000 Sep;224(4):231-9. doi: 10.1046/j.1525-1373.2000.22426.x. Proc Soc Exp Biol Med. 2000. PMID: 10964257 Review.
Cited by
-
RNA vaccines: The dawn of a new age for tuberculosis?Hum Vaccin Immunother. 2025 Dec;21(1):2469333. doi: 10.1080/21645515.2025.2469333. Epub 2025 Feb 27. Hum Vaccin Immunother. 2025. PMID: 40013818 Free PMC article. Review.
-
Intracellular Pathogens: Infection, Immunity, and Intervention.Methods Mol Biol. 2024;2813:1-17. doi: 10.1007/978-1-0716-3890-3_1. Methods Mol Biol. 2024. PMID: 38888767 Review.
References
-
- Aguilar-López B. A., Correa F., Moreno-Altamirano M. M.B., Espitia C., Hernández-Longoria R., Oliva-Ramírez J., et al. . (2019). LprG and PE_PGRS33 mycobacterium tuberculosis virulence factors induce differential mitochondrial dynamics in macrophages. Scandinavian J. Immunol. 89 (1), e12728. doi: 10.1111/sji.12728 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials